What is Bionter?
Bionter operates at the intersection of analytical chemistry and pharmaceutical manufacturing, providing essential infrastructure for the detection and characterization of sub-visible particles. In the complex landscape of biologic drug production, ensuring the absence of particulate matter is a non-negotiable safety standard. By offering advanced testing methodologies, Bionter enables manufacturers to mitigate risks associated with immunogenicity and product stability. The company's focus on high-fidelity particle analysis positions it as a vital partner for global life science organizations striving to meet stringent international regulatory benchmarks for therapeutic safety and efficacy.
How much funding has Bionter raised?
Bionter has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Dynamk Capital
Key Investors in Bionter
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies.
What's next for Bionter?
With the infusion of this latest capital, Bionter is expected to accelerate its research and development initiatives, potentially expanding its suite of analytical tools to accommodate the next generation of complex biologics. The strategic roadmap likely involves scaling its Swiss-based operations to meet international demand and strengthening its market presence through targeted partnerships with major pharmaceutical entities. As the industry shifts toward more rigorous quality assurance protocols, Bionter's specialized expertise in particle characterization will be instrumental in shaping the future of biopharmaceutical manufacturing standards and ensuring the integrity of life-saving therapies.
See full Bionter company page
